Hims & Hers releases Super Bowl ad criticizing pharmaceutical industry and weight loss market, promoting their compounded GLP ...

More than two and a half years after the FDA rejected its migraine treatment, Axsome Therapeutics received an approval for ...

Sev­er­al months in­to a mul­ti­year quest to “rig­or­ous­ly pri­or­i­tize” its pipeline, Take­da is cut­ting a hand­ful of ...

Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart ...

Take­da CEO Christophe We­ber will step down next June af­ter more than 10 years lead­ing the Japan­ese drug­mak­er. Julie ...

Define Ventures identifies about 20 health tech startups, including Innovaccer, Hinge Health & Devoted Health that are poised ...

Roche CEO Schinecker outlines M&A focus on derisked assets, discusses China opportunities, and announces cancellation of four ...

Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form ...

A day after largely fending off criticism of his past controversial comments, HHS nominee Robert F. Kennedy Jr. faced a far ...

Inhibikase Therapeutics is slamming the brakes on its Parkinson’s disease program after the candidate failed to improve ...

Cargo Therapeutics is stopping a Phase 2 study of an experimental CAR-T therapy after the trial generated disappointing data, and it's laying off about half of its workforce as a result.

Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.